Sugi Predict

Sugi Predict / Compounds / SCHEMBL646684

SCHEMBL646684

SCHEMBL646684

COc1cc[c]c2cccc(OC)c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 4/20 0.42
▸ CA2 P00918 4/20 0.42
▸ CA7 P43166 3/20 0.42
▸ CA9 Q16790 3/20 0.42
▸ CA12 O43570 2/20 0.42
▸ CA14 Q9ULX7 2/20 0.42
▸ CA4 P22748 1/20 0.42
▸ ALDH1A1 P00352 5/20 0.39
▸ MAPT P10636 3/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ ALOX15 P16050 2/20 0.39
▸ TP53 P04637 2/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ ALOX12 P18054 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7429237 0.79 MAPT (0.42) ALDH1A1MAPTKDM4EMAPK1LMNA
SCHEMBL4308668 0.76 KDM4E (0.36) ALDH1A1MAPTKDM4EHPGDMAPK1
SCHEMBL2285983 0.75 CA1 (0.42) CA1CA2CA7CA9CA12
SCHEMBL148270 0.75 IDO1 (0.44) CA1CA2CA7CA9CA12
SCHEMBL7753169 0.75 IDO1 (0.44) CA1CA2CA7CA9CA12
SCHEMBL4306879 0.75 CA12 (0.38) CA1CA2CA7CA9CA12
SCHEMBL383902 0.73 CA1 (0.41) CA1CA2CA7CA9CA12
SCHEMBL1098748 0.69 PDE10A (0.41) ALDH1A1KDM4EHPGDLMNAHSD17B10
SCHEMBL942952 0.69 HTR1A (0.44) CA1CA2CA7CA9CA12
SCHEMBL8908078 0.69 CA1 (0.41) CA1CA2CA7CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118103357-A FABP4/5 inhibitors, methods of use and methods of preparation 塞洛拉姆股份有限公司 2024-05-28 — — CN disclosed
CN-117980305-A Spirocyclic pyridine-1, 5-diones exhibiting MNK inhibition and methods of use thereof 4E治疗公司 2024-05-03 — — CN disclosed
US-11883386-B2 Prolyl hydroxylase inhibitors and methods of use AKEBIA THERAPEUTICS, INC. (US) 2024-01-30 — — US disclosed
CN-117279909-A Novel liver selective polyadenylation polymerase inhibitors and methods of use thereof 巴鲁克斯布伦博格研究所 2023-12-22 — — CN disclosed
WO-2023172486-A1 METAL POLYMER COMPLEXES METHODS FOR CARBON DIOXIDE CAPTURE LEHIGH UNIVERSITY (US) 2023-09-14 — — WO disclosed
EP-3768682-B1 2-({2H,3H-[1,4]DIOXINO[2,3-G]QUINOLIN-7-YL}SULFANYL)ACETAMIDE DERIVATIVES AS BCR-ABL KINASE INHIBITORS FOR THE TREATMENT OF CANCER ALLCRON PHARMA INC (US) 2023-07-05 — — EP disclosed
US-20230201178-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE KREOS CAPITAL VII (UK) LIMITED (GB) 2023-06-29 — — US disclosed
US-11685743-B2 Open-shell pi-conjugated molecules exhibiting multidimensional intermolecular covalency, compositions and process for preparing LEHIGH UNIVERSITY 2023-06-27 — — US disclosed
US-20230150931-A1 FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING NOVIUS THERAPEUTICS, LLC (US) 2023-05-18 — — US disclosed
CN-109890814-B Compounds comprising benzo [ D ] [1,3] oxathiolane 3-oxides and methods/uses thereof 普拉马纳制药公司 2023-04-18 — — CN disclosed
EP-1731547-A1 POLYMERIZABLE COMPOUNDS AND USE THEREOF Mitsui Chemicals, Inc. (JP) 2006-12-13 — — EP disclosed
CN-1276035-C Water-color ink MITSUI CHEMICALS INC (JP) 2006-09-20 — — CN disclosed
US-20060178350-A1 7-(2-Cyclohexylidene-ethylidene)-spiro[4.5]decanes UNIVERSITEIT GENT (BE) 2006-08-10 — — US disclosed
CN-1558934-A Water-color ink 三井化学株式会社 2004-12-29 — — CN disclosed
US-20040231558-A1 Has a clear hue, high light fastness and high moisture resistance MITSUI CHEMICALS, INC. (JP) 2004-11-25 — — US disclosed
EP-1441013-A1 WATERCOLOR INK Mitsui Chemicals, Inc. (JP) 2004-07-28 — — EP disclosed
EP-1155698-A1 ORGANOBORON COMPOUNDS EXHIBITING ANTICOCCIDIAL ACTIVITIES Nitto Kasei Co., Ltd. (JP) 2001-11-21 — — EP disclosed
EP-0320742-B1 Process for the after-treatment of developed flexographic printing platens DU PONT (US) 1995-04-05 — — EP disclosed
US-4906551-A Process for the post-treatment of developed relief printing forms for use in flexographic printing HOECHST AKTIENGESELLSCHAFT (DE) 1990-03-06 — — US disclosed
EP-0320742-A2 Process for the after-treatment of developed flexographic printing platens E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-06-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11883386-B2 Prolyl hydroxylase inhibitors and methods of use HIF1AN, EGLN3, HIF1A CA1 1105/4885CA2 509/4885CA7 1035/4885
US-20230201178-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE HIF1AN, EGLN3, HIF1A CA1 1105/4885CA2 509/4885CA7 1035/4885
US-11685743-B2 Open-shell pi-conjugated molecules exhibiting multidimensional intermolecular covalency, compositions and process for preparing INTS6, INTS9, NCLN CA1 4501/4885CA2 4660/4885CA7 4257/4885
US-20060178350-A1 7-(2-Cyclohexylidene-ethylidene)-spiro[4.5]decanes NR3C2, PKD2, REN CA1 3873/4885CA2 2878/4885CA7 479/4885
US-20230150931-A1 FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING FABP5, FABP1, FABP4 CA1 3083/4885CA2 2401/4885CA7 1963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.